DARZALEX FASPRO® dosing schedules for adult patients who are relapsed or refractory*

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib and dexamethasone (3-week cycle) has the same dosing schedule as DARZALEX® (daratumumab) in combination with bortezomib and dexamethasone. DARZALEX FASPRO® is a ready-to-use, single-use vial, which includes a fixed dose and no weight-based calculations.1,2

Dosing frequency decreases over time1
DARZALEX FASPRO® dosing schedule with the DVd regimen
Continue DARZALEX FASPRO® until disease progression or unacceptable toxicity1
Administer medications before and after administration of DARZALEX FASPRO® to minimize systemic ARRs.1

First dose of the every-3-week dosing schedule is given at Week 10.

First dose of the every-4-week dosing schedule is given at Week 25.

*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.

The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.

ARRs=administration-related reactions; DVd=DARZALEX FASPRO® (D) + bortezomib (V) + dexamethasone (d).